New Targets in Inflammation

Jack Botting is Consultant at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane is the Director General at the William Harvey Research Institute, an independent charitable foundation within Queen Mary and Westfield College of the University of London, UK. Sir John Vane shared the Nobel Prize in Physiology or Medicine in 1982 for his discoveries of the mechanism of action of aspirin and of prostacyclin, as well as his work on other prostanoids.

• 1 The history of anti-inflammatory drugs and their mechanism of action.- 2 Structure of prostaglandin H2 synthase-1 (COX-1) and its NSAID binding sites.- 3 Differential inhibition of cyclooxygenases 1 and 2 by NSAIDs.- 4 Blockade of inflammatory hyperalgesia and cyclooxygenase-2.- 5 Brain COX-2 in experimental models of epilepsy and stroke: signalling pathways leading to enhanced expression.- 6 New highly selective cyclooxygenase-2 inhibitors.- 7 Characteristics of cyclooxygenase-1 and cyclooxygenase-2-deficient mice.- 8 X-ray crystal structure of human cyclooxygenase-2.- 9 Risk of gastrointestinal side effects caused by non-steroid anti-inflammatory drugs (NSAIDs).- 10 Expression and regulation of cyclooxygenase-2 in synovial tissues of arthritic patients.- 11 Differential target tissue presentation and COX-1/COX-2 inhibition by non-steroid anti-inflammatory drugs: a rationale for a new classification.- 12 Clinical experience with meloxicam, a selective COX-2 inhibitor.- 13 Enzymatic regulation of the prostaglandin response in a human model of inflammation.- 14 Cyclooxygenase-2 and intestinal cancer.- 15 Cytokines and adhesion molecules in the lung inflammatory response.- 16 Adhesion molecules as targets for therapy in rheumatoid arthritis.